PRVA Privia Health Group Inc

Privia Health Group's stock has shown a decent performance, increasing by 2.1% in the past week. This article examines whether the company's financials, specifically its Return on Equity (ROE) and earnings growth, have contributed to this movement. Despite a low ROE of 3.2% compared to an industry average of 15%, Privia Health Group has achieved an exceptional 52% net income growth over the past five years, largely due to reinvesting all its profits back into the business.

This article from Zacks Analyst Blog highlights how Hims & Hers Health (HIMS), Biotricity (BTCY), and Privia Health (PRVA) have shown strong performance in the healthcare IT sector in 2025. These companies have leveraged digital transformation, with Hims & Hers focusing on telehealth, Biotricity on remote patient monitoring, and Privia Health on physician-enablement technology, all achieving over 20% growth. The article examines their growth catalysts and risks as the U.S. healthcare IT market continues to expand significantly.

Privia Health Group, Inc. (NASDAQ:PRVA) has received a consensus "Moderate Buy" rating from analysts, with an average one-year price target of $30.42. Insider selling recently occurred, as CFO David Mountcastle and Director Matthew Shawn Morris sold shares in December. Despite a high institutional ownership of 94.48% and a market cap of $2.92 billion, the company has a stretched valuation with a P/E ratio of 182.55, and analysts forecast an FY EPS of approximately $0.14.

Privia Health Group, Inc. has seen a shift in its valuation grade, moving from an expensive to a more attractive standing. The company demonstrates a high P/E ratio of 181 but has also achieved significant operating cash flow of USD 91.86 million and net sales of USD 521.15 million in June 2025, contributing to positive financial sentiment. This adjustment reflects evolving market dynamics within the insurance sector.

Riverbridge Partners LLC reduced its stake in Privia Health Group (NASDAQ:PRVA) by 6.3% in Q3, now holding 4,633,867 shares valued at $115.38 million. Insider transactions on December 12th saw Director Matthew Shawn Morris and CFO David Mountcastle sell a combined total of over $930,000 worth of stock. Analysts currently rate PRVA as a "Moderate Buy" with a consensus price target of $30.42.

Analysts maintain a bullish outlook on select healthcare stocks, specifically Nuvalent (NUVL) and Privia Health Group (PRVA). Truist Financial and Barclays reaffirmed Buy ratings for Nuvalent, predicting a significant upside. Similarly, Truist Financial reiterated a Buy rating for Privia Health Group, also forecasting a strong upside.